FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage

The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.

Topics

FDA warns companies over unapproved weight loss drug sales

The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, ...
The Hill - 1d
In shift, RFK Jr. now says weight-loss drugs 'have a place'

His remarks come days before he holds confirmation meetings with GOP senators.
ABC News - 6d
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly

It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
CNBC - Dec. 11
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products
ABC News - Dec. 5
Weight-loss drug Mounjaro 'changed my life,' says mother-of-two

People struggling with their weight welcome the NHS rollout of Mounjaro but worry about delays.
BBC News - Dec. 5
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
CNBC - Dec. 5
Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance

The health care giant’s David Ricks defended the agency’s role in reviewing data and ensuring drug safety.
The New York Times - Dec. 4
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy

Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
MarketWatch - Dec. 4
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
CNBC - Dec. 4

FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage

Topics

Related

FDA warns companies over unapproved weight loss drug sales

In shift, RFK Jr. now says weight-loss drugs 'have a place'

Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Weight-loss drug Mounjaro 'changed my life,' says mother-of-two

Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance

Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

More from CNBC

House Republicans race to find a Trump-backed path to avoid government shutdown

Micron stock headed for worst day since 2020 after disappointing guidance

Luigi Mangione hit with federal murder, stalking charges in UnitedHealthcare CEO killing

Nike will report earnings after the bell. Here's what Wall Street expects

What the top 75 college sports programs are worth